Genic Co., Ltd

Genic Co., Ltd

KKRX:123330
16,830.00
KRW
-480.00
(-2.77%)
2,408.66EPS
12.97P/E
244.52BMarket Cap
Nov 12Next Earn
2013 Y
2014 Y
2015 Y
2016 Y
2017 Y
2018 Y
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
TTM
Revenue per Share
8,862.55
9,242.41
10,726.68
13,037.92
9,434.24
10,068.52
6,292.62
6,145.42
5,605.24
4,585.46
4,092.14
6,836.86
9,994.99
11,467.15
Basic EPS, GAAP
492.09
284.67
425.65
178.16
-1,089
-2,235
-1,744
-635
-632
-487
-643
1,036
2,414
2,408.66
Free Cash Flow per Basic Share
-726.12
-812.27
-1,413.8
-974.61
-1,894.06
-1,759.56
73.03
-82.17
280.07
-180.35
-161.77
-188.85
2,296.46
729.92
Dividend per Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Book Value per Share
8,469.36
8,441.7
8,866.41
9,486.21
7,994.72
5,679.83
3,958.51
3,257.13
2,814.65
2,325.39
1,681.95
2,831.35
5,245.91
5,694.22
Tangible Book Value per Share
8,415.72
8,392.22
8,467.98
9,057.51
7,610.97
5,327.24
3,908.86
3,233.92
2,805.7
2,322.06
1,679.51
2,829.85
5,242.92
5,691.32
Basic Weighted Avg Shares
7
7
7
7
7
7
7
7
7
7
7
7
8
8
Sales/Revenue/Turnover
62,179
63,520
73,706
89,668
64,690
69,027
43,151
42,132
38,408
31,449
28,070
49,908
78,198
89,727
Operating Margin (%)
6.22
3.01
4.23
5.44
-12.81
-16.42
-2.66
2.47
-10.26
-9.06
-14.32
12.07
19.15
16.3
Depreciation Expense
2,949
3,325
4,092
4,086
3,786
4,793
4,261
3,025
2,313
1,883
1,801
1,637
1,969
2,200
Net Income, GAAP
3,452
1,956
2,925
1,225
-7,467
-15,323
-11,959
-4,353
-4,331
-3,340
-4,411
7,563
18,887
18,847
Effective Tax Rate (%)
20.89
17.19
13.75
38.38
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Profit Margin (%)
5.55
3.08
3.97
1.37
-11.54
-22.2
-27.71
-10.33
-11.28
-10.62
-15.71
15.15
24.15
21
Working Capital
23,577
24,630
19,010
26,419
5,183
9,538
-3,571
3,686
13,841
1,198
-2,252
5,550
17,875
18,940
LT Debt
2,092
8,300
10,229
18,659
11,693
10,322
315
9,447
10,298
56
47
657
2,111
2,090
Total Equity
53,246
55,158
58,041
61,931
54,273
38,941
27,140
22,331
19,297
15,943
11,531
22,154
41,048
44,556
Return on Invested Capital (%)
5.61
2.66
3.88
4.03
- -
- -
- -
2.13
- -
- -
- -
- -
- -
- -
Return on Capital (%)
6.35
3.34
4.52
1.84
- -
- -
- -
-7.5
- -
- -
- -
- -
- -
- -
Return on Common Equity (%)
6.51
3.61
5.17
2.04
-12.85
-32.88
-36.2
-17.6
-20.81
-18.96
-32.11
44.9
59.77
53.67

Capital Structure

KRW

•

in mil. unless spec.
Sep'25
Dec'25
Mar'26
ST Debt
5,279
599
629
LT Borrowings
- -
- -
- -
LT Finance Leases
728
2,111
2,090
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
8
8
8
Market Capitalization
192,879
129,264
244,521

Working Capital

KRW

•

in mil. unless spec.
Sep'25
Dec'25
Mar'26
Total Current Assets
32,899
30,897
38,835
Cash, Cash Equivalents & STI
11,843
13,247
5,394
Accounts Receivable, Net
14,095
6,203
20,489
Inventories
6,616
11,060
12,391
Total Current Liabilities
14,476
13,021
19,895
Payables & Accruals
- -
- -
- -
ST Debt
5,279
599
629
Deferred Revenue
- -
- -
- -

Growth Rates

KRW

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
3.68%
23.75%
85.28%
Free Cash Flow
-225.55%
-398.89%
-1,403.3%
Net Income, GAAP
-86.1%
-22.62%
149.73%
Sales/Revenue/Turnover
5.74%
19.36%
56.68%
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

KRW

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
6,364
8,974
15,131
19,439
49,908
2025
17,828
24,649
23,555
12,166
78,198
2026
29,356
- -
- -
- -
- -

Quarterly Earnings Per Share

KRW

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
-92
115
267
704.32
1,036
2025
449
511.16
674.5
778.76
2,414
2026
444.24
- -
- -
- -
- -

Quarterly Dividends Per Share

KRW

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -
2026
- -
- -
- -
- -
- -

Company Description

CEO
Nam Heo
Full Time Employees
385
Sector
Health technology
Industry
Pharmaceuticals: major
Address
Seongnam-si South Korea
IPO Date
Aug 2, 2011
Business
Genic Co., Ltd. is a South Korea-based cosmetic research, development, and manufacturing company primarily engaged in the original equipment manufacturing (OEM) and original design manufacturing (ODM) of skincare, hydrogel mask packs, and personal care products. Founded in 2001 and headquartered in Seoul, South Korea, with core production facilities in Nonsan, South Chungcheong Province, the company is listed on the KOSDAQ market of the Korea Exchange under the ticker symbol 123330. Genic operates across two primary business divisions: OEM/ODM contract manufacturing services for third-party domestic and multinational beauty brands, and the development, marketing, and distribution of proprietary consumer cosmetic brands. The company offers a comprehensive range of beauty and personal care products across multiple specialized categories: hydrogel and sheet mask systems, including temperature-sensitive water-soluble hydrogel facial masks, hydrogel under-eye patches, soothing spot patches, bio-cellulose sheet masks, microfiber sheet masks, modeling masks, and transdermal micro-needle patch formulations; basic and functional skincare treatments, comprising deep-hydration ampoules, anti-aging serums, brightening essences, facial toners, emulsions, barrier creams, and eye creams; sun care and specialty protection products, encompassing UV-blocking sun cushions, sun creams, cooling sun gels, and hydrogel outdoor sport sun patches; cleansing and personal care solutions, including foam cleansers, cleansing oils, micellar waters, body lotions, body washes, hand creams, and hair care formulations; and proprietary brand offerings, marketed under commercial labels such as Celderma, Celderma Daily, and Purebess across television home shopping networks, online retail platforms, duty-free outlets, and beauty specialty stores. The company maintains domestic operations and international facilities, including a manufacturing subsidiary in Shanghai, China, catering to distribution networks across South Korea, China, North America, Europe, Southeast Asia, and Japan. In recent developments, Genic Co., Ltd. has expanded its international OEM and ODM supply partnerships to satisfy accelerating global demand for hydrogel-based skincare and sun-protection patches across North American and European retail markets. The company has executed operational and technological upgrades at its Nonsan manufacturing complex, expanding cleanroom infrastructure and automating hydrogel production lines to increase manufacturing capacity and improve operational cost efficiencies. Additionally, Genic has advanced its research and development initiatives toward the commercialization of eco-friendly, biodegradable hydrogel sheet materials and active-ingredient delivery systems, while restructuring its sales distribution strategy to prioritize high-margin cross-border e-commerce and direct-to-consumer global channels.